Health Care • Biotechnology: Laboratory Analytical Instruments
$2.90 ▲ +0.07
(+2.47%)
MKT CAP: $901.4M • VOL: 11.97M
52W L $1 52W H $3
ROARABLE / RQD
D- • 37/100
PIOTROSKI
3 / 9
PACB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $160.0M | $154.0M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $45.8M | $37.3M | — |
| Gross Margin % | 28.6% | 24.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$553.9M | -$474.3M | -$334.5M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$546.4M | -$309.9M | -$306.7M |
| EBITDA (Normalized) | -$551.7M | -$469.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$111.2M | -$206.1M | -$259.2M |
| Capital Expenditures (CapEx) | $2.7M | $6.2M | — |
| Free Cash Flow (FCF) | -$113.9M | -$212.2M | -$259.2M |
| FCF Margin % | -71.2% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $63.7M | $55.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $5.3M | $506.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PACB.